MENU
+Compare
ANAB
Stock ticker: NASDAQ
AS OF
Dec 20, 04:59 PM (EDT)
Price
$14.50
Change
-$0.50 (-3.33%)
Capitalization
441.22M

ANAB AnaptysBio Forecast, Technical & Fundamental Analysis

a provider of therapeutic antibodies for inflammation and immuno-oncology

Industry Biotechnology
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for ANAB with price predictions
Dec 20, 2024

ANAB sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for ANAB moved below the 200-day moving average on December 04, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 10, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ANAB as a result. In of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ANAB turned negative on December 11, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ANAB entered a downward trend on November 27, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ANAB advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

ANAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.247) is normal, around the industry mean (14.538). P/E Ratio (0.000) is within average values for comparable stocks, (87.654). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.759). ANAB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (6.978) is also within normal values, averaging (254.760).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ANAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ANAB is expected to report earnings to rise 42.98% to -162 cents per share on February 27

AnaptysBio ANAB Stock Earnings Reports
Q4'24
Est.
$-1.63
Q3'24
Beat
by $0.56
Q2'24
Missed
by $0.67
Q1'24
Missed
by $0.05
Q4'23
Beat
by $0.04
The last earnings report on November 05 showed earnings per share of -113 cents, beating the estimate of -170 cents. With 1.59M shares outstanding, the current market capitalization sits at 441.22M.
A.I. Advisor
published General Information

General Information

a provider of therapeutic antibodies for inflammation and immuno-oncology

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
10770 Wateridge Circle
Phone
+1 858 362-6295
Employees
117
Web
https://www.anaptysbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CVLFX13.420.13
+0.98%
Cullen Value C
FCUEX19.160.18
+0.95%
NYLI PineStone U.S. Equity Class A
AEYIX8.340.06
+0.72%
American Century Equity Income C
JIHIX16.05-0.02
-0.12%
JPMorgan International Hedged Equity I
JSGIX27.65-2.27
-7.59%
JHancock U.S. Growth I

ANAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with CLRB. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then CLRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANAB
1D Price
Change %
ANAB100%
-3.33%
CLRB - ANAB
51%
Loosely correlated
-1.26%
ADCT - ANAB
40%
Loosely correlated
-7.55%
HRMY - ANAB
39%
Loosely correlated
+1.15%
AMRN - ANAB
38%
Loosely correlated
+2.49%
AURA - ANAB
35%
Loosely correlated
+1.23%
More